The pharmaceutical business model relies on a simple cycle. Companies invest billions into research, secure a period of market exclusivity […]

The global pharmaceutical industry currently faces a historic loss-of-exclusivity super-cycle. Between 2025 and 2030, an estimated $200 billion to $400

The pharmaceutical supply chain is a system where the loss of exclusivity for a brand-name drug creates a massive transfer

The pharmaceutical industry is approaching a singularity. Between 2025 and 2030, a wave of patent expirations—often described as the “super-cliff”—will

The foundational error in pharmaceutical valuation lies in conflating the statutory patent term with commercial exclusivity. Generalist investors and market

Big pharma used to treat loss of exclusivity as a weather event. You saw the date on the Gantt chart,

The business model for off-patent medicine is undergoing a forced evolution. For four decades, the Hatch-Waxman Act provided a predictable

The pharmaceutical sector operates on a punishing mathematical divide. In 2024, generic and biosimilar medicines filled 90% of all prescriptions

The Convergence of Federal Exclusivity and Public Health Necessity The pharmaceutical industry operates on a fundamental tension between two opposing